Many patients with moderately severe or worse chronic obstructive pulmonary disease (COPD) are receiving an inhaled corticosteroid (ICS) in addition to a long-acting beta-agonist (LABA) and/or a ...

Treatment with inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) may reduce the risk of death from pneumonia and other causes although they are associated an ...

A Cochrane systematic review has found new moderate-quality evidence that tiotropium + long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS) combination therapy reduces hospital admission for ...

Interventions to de-escalate use of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) are necessary and beneficial, researchers said during the federal ...

A study looking at chronic obstructive pulmonary disease (COPD) and coronary heart disease found that inhaled corticosteroids (ICS) reduced future cardiac events in patients not known to have coronary ...

Findings support the most recent Global Initiative for Chronic Obstructive Lung Disease recommendations and the European Respiratory Society Task Force report on ICS withdrawal in COPD. The study ...

The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

Researchers from the UK caution that inhaled corticosteroids (ICS) are being overused in patients with chronic obstructive pulmonary disease (COPD), in light of a lack of solid evidence for their ...

Background and Goal: Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have ...

Please provide your email address to receive an email when new articles are posted on . Fluticasone-based inhaled corticosteroid treatment substantially changed airway microbiome diversity in patients ...

Despite recommendations since 2007 limiting ICS use in patients with either forced expiratory volume in 1 s (FEV 1) <50% or frequent exacerbations, or both, 1,6 ICS are widely prescribed across all ...